February 3, 2022
Life Sciences
  • Merck & Co. said it expects its sales to surge by up to 18 percent in 2022 compared with last year, primarily driven by demand for the COVID-19 antiviral pill molnupiravir. Merck said sales of the drug, which it developed with Ridgeback Biotherapeutics LP, reached $952 million in the fourth quarter of 2021, and that it expects another $5 to $6 billion this year. (Article here)